Danish drugmaker Novo Nordisk plans to invest 8.5 billion Danish kroner (about €1.14 billion) to establish a new production facility in Odense, Denmark.
Novo Nordisk is to acquire Cardior Pharmaceuticals for up to €1.025 billion Euros, including an upfront payment and additional payments if certain development and...
Novo Nordisk wants to make another major capital investment in production capacity for its diabetes and obesity therapies. The Danish drugmaker announced to spend more...
Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up...
Danish drugmaker Novo Nordisk is in exclusive talks to take a controlling stake in Biocorp, a French company specializing in developing and producing delivery systems and...
04.04.2016
- FeF Chemicals is a well-known name and a leading global supplier of ingredients for the pharmaceutical industry. Having been a part of the Danish healthcare corporation Novo...
04.01.2011
- Anne Phillips, M.D., has been appointed as Novo Nordisk's as vice president, Clinical Development, Medical and Regulatory Affairs for North America. Dr. Phillips reports directly...
